Cargando…

Bridging Sunitinib Exposure to Time‐to‐Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker

Hepatocellular carcinoma (HCC) is third in cancer‐related causes of death worldwide and its treatment is a significant unmet medical need. Sunitinib is a selective tyrosine kinase inhibitor of the angiogenic biomarker: soluble vascular endothelial growth factor receptor‐2 (sVEGFR(2)). Sunitinib fail...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ait‐Oudhia, S, Mager, DE, Pokuri, V, Tomaszewski, G, Groman, A, Zagst, P, Fetterly, G, Iyer, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5131886/ https://www.ncbi.nlm.nih.gov/pubmed/27300260 http://dx.doi.org/10.1002/psp4.12084

Ejemplares similares

Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics
por: Ait-Oudhia, S, et al.
Publicado: (2012)

The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles()
por: Gaustad, Jon-Vidar, et al.
Publicado: (2017)

Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
por: Ait-Oudhia, Sihem, et al.
Publicado: (2014)

Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study
por: Samuel, Sandeep, et al.
Publicado: (2018)

Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy
por: Sahani, Dushyant V, et al.
Publicado: (2013)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher, Brett, et al.
Publicado: (2016)

Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma
por: Mizuno, Ryuichi, et al.
Publicado: (2017)

Anti-Angiogenic Treatment (Sunitinib) for Disseminated Malignant Haemangiopericytoma: A Case Study and Review of the Literature
por: Delgado, M., et al.
Publicado: (2011)

Mathematical bridges
por: Andreescu, Titu, et al.
Publicado: (2017)

Combination effects of platinum drugs and N(1), N(11) diethylnorspermine on spermidine/spermine N(1)-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants
por: Tummala, Ramakumar, et al.
Publicado: (2010)

Marginal increase of sunitinib exposure by grapefruit juice
por: van Erp, Nielka P., et al.
Publicado: (2010)

Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib
por: Beltran, Himisha, et al.
Publicado: (2014)

Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: Is this an anti-angiogenic potentiation of cancer?
por: Mete, Uttam K., et al.
Publicado: (2015)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

Immunohistochemical angiogenic biomarkers in hepatocellular carcinoma and cirrhosis: correlation with pathological features
por: Ribeiro, Osmar Damasceno, et al.
Publicado: (2016)

A Comparative Study of Serum Angiogenic Biomarkers in Cirrhosis and Hepatocellular Carcinoma
por: Pocino, Krizia, et al.
Publicado: (2021)

Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
por: Harmon, Charles S, et al.
Publicado: (2011)

Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere?
por: Tan, Chun Han Nigel, et al.
Publicado: (2018)

A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring
por: Fleisher, Brett, et al.
Publicado: (2017)

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
por: de Wit, Djoeke, et al.
Publicado: (2014)

Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
por: Jiménez-Fonseca, Paula, et al.
Publicado: (2018)

Key sunitinib‐related biomarkers for renal cell carcinoma
por: Peng, Yun, et al.
Publicado: (2021)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Bridging the gap to university mathematics
por: Hurst, Edward, et al.
Publicado: (2009)

A mathematical bridge: an intuitive journey in higher mathematics
por: Hewson, Stephen
Publicado: (2009)

Mechanisms, monitoring, and management of tyrosine kinase inhibitors–associated cardiovascular toxicities
por: Chaar, Maher, et al.
Publicado: (2018)

Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis
por: Nguyen, Linh, et al.
Publicado: (2016)

The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia
por: Nikuei, Pooneh, et al.
Publicado: (2015)

AMGET, an R-Based Postprocessing Tool for ADAPT 5
por: Guiastrennec, B, et al.
Publicado: (2013)

In vitro to clinical translational pharmacokinetic/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization
por: Mody, Hardik, et al.
Publicado: (2023)

Interest-rate management
por: Zagst, Rudi
Publicado: (2002)

Biomarkers for Anti-Angiogenic Therapy in Cancer
por: Wehland, Markus, et al.
Publicado: (2013)

Inflammatory and angiogenic biomarkers in diabetic retinopathy
por: Kaštelan, Snježana, et al.
Publicado: (2020)

Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy
por: Kasprzak, Aldona, et al.
Publicado: (2018)

Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma
por: Msaouel, Pavlos, et al.
Publicado: (2017)

Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response
por: Qi, Xiaoqiang, et al.
Publicado: (2020)

Multifunctional Nanoplatform Based on Sunitinib for Synergistic Phototherapy and Molecular Targeted Therapy of Hepatocellular Carcinoma
por: Xu, Wenjing, et al.
Publicado: (2023)

Building bridges II: mathematics of László Lovász
por: Bárány, Imre, et al.
Publicado: (2019)

Building bridges: between mathematics and computer science
por: Grötschel, Martin, et al.
Publicado: (2008)

Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
por: Franco, Yesenia L, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mbv2v6s2rmd94m49e0i348qqh5